Cirina Ltd. - Company Profile

...first Asian companies built around liquid biopsy tests for early cancer detection was Hong Kong-based Cirina Ltd....
...licensed the technology to Take2 Health Ltd. in 2019. Decheng was the sole investor in Cirina’s...

Take2 licenses Grail’s nasopharyngeal cancer detection platform

...BioCentury the company gained the technology in 2017 when it acquired cancer diagnostics developer Cirina Ltd. Cirina...
...co-founder and member of its scientific advisory board following the merger (see "Grail Merging with Cirina"...
...Hong Kong, where Lo is a professor of medicine and chemical pathology, and IP from Cirina...

...The team has filed a patent application covering its findings. Lo co-founded cancer diagnostic company Cirina Ltd....
...He became a scientific co-founder of circulating tumor-derived cfDNA (ctDNA) testing company Grail Inc., after Cirina...

...tests for early cancer detection. Last year, Grail merged with Hong Kong cancer diagnostics developer Cirina Ltd....
...on Asia. Grail Head of R&D Alex Aravanis told BioCentury last June that expertise from Cirina...

Grail declines comment on Hong Kong IPO plans

...cancer diagnostics developer Cirina Ltd., which became Grail’s Southeast Asia-focused subsidiary. In connection with the merger, Cirina...
...joined its scientific advisory board. Min Cui of Decheng Capital, which invested $12 million in Cirina’s...
...only funding round, also joined Grail’s board (see BioCentury Extra, May 31, 2017) . Jaime De Leon Cirina Ltd. Grail...

Liquid biopsy test detects nasopharyngeal cancer in asymptomatic patients

...at Chinese University of Hong Kong are co-founders of cancer diagnostic company Cirina Ltd. In May, Cirina...
...company led to the merger, but told BioCentury the two companies’ portfolios were complementary, with Cirina...
...test to identify people at risk for nasopharyngeal carcinoma based on the results and the Cirina...